Avik Banerjee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Avik Banerjee has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Vadim Gaponenko
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL 60607, USA
11 shared publications - Ruth Nussinov
Frederick National Laboratory for Cancer Research
7 shared publications Hyunbum Jang
Cancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, U.S.A
4 shared publications- Hyunbum Jang
Frederick National Laboratory for Cancer Research
4 shared publications Shaoyong Lu
Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Children’s Medical Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, 200127, China
3 shared publicationsHazem Abdelkarim
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, USA
2 shared publications
Latest Publications
- Open Access
- 18 November 2025
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 375
Therapeutic targeting of endothelial calcium signaling accelerates the resolution of lung injury
Acute respiratory distress syndrome (ARDS) is a severe pulmonary disease characterized by acute, noncardiogenic pulmonary edema and hypoxemia leading to respiratory failure. It is induced by a diverse array of etiologies, including recent SARS-CoV-2 infection. The current standard of care for ARDS remains predominantly supportive, underscoring the urgent need for targeted pharmacological interventions. To address this critical gap, we developed an inhibitor of the microtubule accessory factor end-binding protein 3 (EB3), a key mediator of pathological calcium signaling in endothelial cells. During injury, EB3 facilitates inositol 1,4,5-trisphosphate receptor 3 (IP 3 R3) clustering on the endoplasmic reticulum membrane, activating widespread calcium release from intracellular stores and leading to endothelial barrier disruption. Using nuclear magnetic resonance (NMR)-guided approaches, we designed and optimized a synthetic EB3 inhibitor, termed vascular therapeutics (VT)-109, with enhanced physicochemical properties. We evaluated the therapeutic potential of VT-109 across a wide range of preclinical models in which pathogenic insults target epithelial or endothelial barriers. Treatment with VT-109 promptly restored the tissue‒fluid balance in the injured lung by inducing the reannealing of VE-cadherin junctions and restoring the endothelial barrier. In addition to vascular protection, VT-109 improved lung architecture and function, normalized immune responses, and significantly reduced both morbidity and mortality in ARDS models. At the molecular level, VT-109 blocks inflammatory NFAT and NF κ B signaling while concurrently activating FOXM1-dependent endothelial regeneration. These findings support EB3 inhibition as a promising therapeutic strategy for ARDS and highlight VT-109 as a versatile drug candidate capable of addressing the multifaceted pathophysiology of this disease.
- 18 November 2025
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 375
Open AccessTherapeutic targeting of endothelial calcium signaling accelerates the resolution of lung injury
Acute respiratory distress syndrome (ARDS) is a severe pulmonary disease characterized by acute, noncardiogenic pulmonary edema and hypoxemia leading to respiratory failure. It is induced by a diverse array of etiologies, including recent SARS-CoV-2 infection. The current standard of care for ARDS remains predominantly supportive, underscoring the urgent need for targeted pharmacological interventions. To address this critical gap, we developed an inhibitor of the microtubule accessory factor end-binding protein 3 (EB3), a key mediator of pathological calcium signaling in endothelial cells. During injury, EB3 facilitates inositol 1,4,5-trisphosphate receptor 3 (IP 3 R3) clustering on the endoplasmic reticulum membrane, activating widespread calcium release from intracellular stores and leading to endothelial barrier disruption. Using nuclear magnetic resonance (NMR)-guided approaches, we designed and optimized a synthetic EB3 inhibitor, termed vascular therapeutics (VT)-109, with enhanced physicochemical properties. We evaluated the therapeutic potential of VT-109 across a wide range of preclinical models in which pathogenic insults target epithelial or endothelial barriers. Treatment with VT-109 promptly restored the tissue‒fluid balance in the injured lung by inducing the reannealing of VE-cadherin junctions and restoring the endothelial barrier. In addition to vascular protection, VT-109 improved lung architecture and function, normalized immune responses, and significantly reduced both morbidity and mortality in ARDS models. At the molecular level, VT-109 blocks inflammatory NFAT and NF κ B signaling while concurrently activating FOXM1-dependent endothelial regeneration. These findings support EB3 inhibition as a promising therapeutic strategy for ARDS and highlight VT-109 as a versatile drug candidate capable of addressing the multifaceted pathophysiology of this disease.
- Open Access
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
Data‐driven model of the KRas4B/Calmodulin complex
KRas4B (henceforth called KRas) is a small GTPase that regulates activation of a variety of signaling pathways, including the Raf/MEK/ERK pathway, leading to cell proliferation, survival, and differentiation. Activation of these signaling pathways is dependent on the nucleotide‐bound state of KRas: GTP‐bound KRas “turns on” signaling while GDP‐bound KRas “turns off” signaling. Interestingly, KRas is the only one of the three Ras isoforms that interacts with Ca 2+ ‐bound calmodulin (CaM). However, attempts to crystallize the KRas/CaM complex have proven difficult due to the flexible nature of the hypervariable region (HVR) of KRas as well as the linker region of CaM. We present a model of the complex containing unprocessed full‐length KRas in complex with CaM, guided by small angle x‐ray scattering (SAXS), NMR nuclear overhouser effects and chemical shift perturbations. The low‐resolution envelope of the complex shows that CaM interacts with KRas in an open conformation. The NOEs suggest that the HVR adopts a helical conformation in the region that interacts with CaM. Our low‐resolution experimental data, together with published chemical shift perturbations lead to a model of the KRas/CaM complex that fits our SAXS envelop well (ꭓ=1.97). This model will be refined using molecular dynamics simulations.
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
Open AccessData‐driven model of the KRas4B/Calmodulin complex
KRas4B (henceforth called KRas) is a small GTPase that regulates activation of a variety of signaling pathways, including the Raf/MEK/ERK pathway, leading to cell proliferation, survival, and differentiation. Activation of these signaling pathways is dependent on the nucleotide‐bound state of KRas: GTP‐bound KRas “turns on” signaling while GDP‐bound KRas “turns off” signaling. Interestingly, KRas is the only one of the three Ras isoforms that interacts with Ca 2+ ‐bound calmodulin (CaM). However, attempts to crystallize the KRas/CaM complex have proven difficult due to the flexible nature of the hypervariable region (HVR) of KRas as well as the linker region of CaM. We present a model of the complex containing unprocessed full‐length KRas in complex with CaM, guided by small angle x‐ray scattering (SAXS), NMR nuclear overhouser effects and chemical shift perturbations. The low‐resolution envelope of the complex shows that CaM interacts with KRas in an open conformation. The NOEs suggest that the HVR adopts a helical conformation in the region that interacts with CaM. Our low‐resolution experimental data, together with published chemical shift perturbations lead to a model of the KRas/CaM complex that fits our SAXS envelop well (ꭓ=1.97). This model will be refined using molecular dynamics simulations.
- Open Access
- 14 November 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (22) , 5718
The Hypervariable Region of K-Ras4B Governs Molecular Recognition and Function
The flexible C-terminal hypervariable region distinguishes K-Ras4B, an important proto-oncogenic GTPase, from other Ras GTPases. This unique lysine-rich portion of the protein harbors sites for post-translational modification, including cysteine prenylation, carboxymethylation, phosphorylation, and likely many others. The functions of the hypervariable region are diverse, ranging from anchoring K-Ras4B at the plasma membrane to sampling potentially auto-inhibitory binding sites in its GTPase domain and participating in isoform-specific protein–protein interactions and signaling. Despite much research, there are still many questions about the hypervariable region of K-Ras4B. For example, mechanistic details of its interaction with plasma membrane lipids and with the GTPase domain require further clarification. The roles of the hypervariable region in K-Ras4B-specific protein–protein interactions and signaling are incompletely defined. It is also unclear why post-translational modifications frequently found in protein polylysine domains, such as acetylation, glycation, and carbamoylation, have not been observed in K-Ras4B. Expanding knowledge of the hypervariable region will likely drive the development of novel highly-efficient and selective inhibitors of K-Ras4B that are urgently needed by cancer patients.
- 14 November 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (22) , 5718
Open AccessThe Hypervariable Region of K-Ras4B Governs Molecular Recognition and Function
The flexible C-terminal hypervariable region distinguishes K-Ras4B, an important proto-oncogenic GTPase, from other Ras GTPases. This unique lysine-rich portion of the protein harbors sites for post-translational modification, including cysteine prenylation, carboxymethylation, phosphorylation, and likely many others. The functions of the hypervariable region are diverse, ranging from anchoring K-Ras4B at the plasma membrane to sampling potentially auto-inhibitory binding sites in its GTPase domain and participating in isoform-specific protein–protein interactions and signaling. Despite much research, there are still many questions about the hypervariable region of K-Ras4B. For example, mechanistic details of its interaction with plasma membrane lipids and with the GTPase domain require further clarification. The roles of the hypervariable region in K-Ras4B-specific protein–protein interactions and signaling are incompletely defined. It is also unclear why post-translational modifications frequently found in protein polylysine domains, such as acetylation, glycation, and carbamoylation, have not been observed in K-Ras4B. Expanding knowledge of the hypervariable region will likely drive the development of novel highly-efficient and selective inhibitors of K-Ras4B that are urgently needed by cancer patients.
- 10 November 2019
- Published by Springer Nature
- Vol. 1163, 171-186
Advances in NMR Methods to Identify Allosteric Sites and Allosteric Ligands
NMR allows assessment of protein structure in solution. Unlike conventional X-ray crystallography that provides snapshots of protein conformations, all conformational states are simultaneously accessible to analysis by NMR. This is a significant advantage for discovery and characterization of allosteric effects. These effects are observed when binding at one site of the protein affects another distinct site through conformational transitions. Allosteric regulation of proteins has been observed in multiple physiological processes in health and disease, providing an opportunity for the development of allosteric inhibitors. These compounds do not directly interact with the orthosteric site of the protein but influence its structure and function. In this book chapter, we provide an overview on how NMR methods are utilized to identify allosteric sites and to discover novel inhibitors, highlighting examples from the field. We also describe how NMR has contributed to understanding of allosteric mechanisms and propose that it is likely to play an important role in clarification and further development of key concepts of allostery.
- 10 November 2019
- Published by Springer Nature
- Vol. 1163, 171-186
Advances in NMR Methods to Identify Allosteric Sites and Allosteric Ligands
NMR allows assessment of protein structure in solution. Unlike conventional X-ray crystallography that provides snapshots of protein conformations, all conformational states are simultaneously accessible to analysis by NMR. This is a significant advantage for discovery and characterization of allosteric effects. These effects are observed when binding at one site of the protein affects another distinct site through conformational transitions. Allosteric regulation of proteins has been observed in multiple physiological processes in health and disease, providing an opportunity for the development of allosteric inhibitors. These compounds do not directly interact with the orthosteric site of the protein but influence its structure and function. In this book chapter, we provide an overview on how NMR methods are utilized to identify allosteric sites and to discover novel inhibitors, highlighting examples from the field. We also describe how NMR has contributed to understanding of allosteric mechanisms and propose that it is likely to play an important role in clarification and further development of key concepts of allostery.
- 2 October 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 11 (550)
The bacterial Ras/Rap1 site-specific endopeptidase RRSP cleaves Ras through an atypical mechanism to disrupt Ras-ERK signaling
The Ras–extracellular signal–regulated kinase pathway is critical for controlling cell proliferation, and its aberrant activation drives the growth of various cancers. Because many pathogens produce toxins that inhibit Ras activity, efforts to develop effective Ras inhibitors to treat cancer could be informed by studies of Ras inhibition by pathogens. Vibrio vulnificus causes fatal infections in a manner that depends on multifunctional autoprocessing repeats-in-toxin, a toxin that releases bacterial effector domains into host cells. One such domain is the Ras/Rap1-specific endopeptidase (RRSP), which site-specifically cleaves the Switch I domain of the small GTPases Ras and Rap1. We solved the crystal structure of RRSP and found that its backbone shares a structural fold with the EreA/ChaN-like superfamily of enzymes. Unlike other proteases in this family, RRSP is not a metalloprotease. Through nuclear magnetic resonance analysis and nucleotide exchange assays, we determined that the processing of KRAS by RRSP did not release any fragments or cause KRAS to dissociate from its bound nucleotide but instead only locally affected its structure. However, this structural alteration of KRAS was sufficient to disable guanine nucleotide exchange factor–mediated nucleotide exchange and prevent KRAS from binding to RAF. Thus, RRSP is a bacterial effector that represents a previously unrecognized class of protease that disconnects Ras from its signaling network while inducing limited structural disturbance in its target.
- 2 October 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 11 (550)
The bacterial Ras/Rap1 site-specific endopeptidase RRSP cleaves Ras through an atypical mechanism to disrupt Ras-ERK signaling
The Ras–extracellular signal–regulated kinase pathway is critical for controlling cell proliferation, and its aberrant activation drives the growth of various cancers. Because many pathogens produce toxins that inhibit Ras activity, efforts to develop effective Ras inhibitors to treat cancer could be informed by studies of Ras inhibition by pathogens. Vibrio vulnificus causes fatal infections in a manner that depends on multifunctional autoprocessing repeats-in-toxin, a toxin that releases bacterial effector domains into host cells. One such domain is the Ras/Rap1-specific endopeptidase (RRSP), which site-specifically cleaves the Switch I domain of the small GTPases Ras and Rap1. We solved the crystal structure of RRSP and found that its backbone shares a structural fold with the EreA/ChaN-like superfamily of enzymes. Unlike other proteases in this family, RRSP is not a metalloprotease. Through nuclear magnetic resonance analysis and nucleotide exchange assays, we determined that the processing of KRAS by RRSP did not release any fragments or cause KRAS to dissociate from its bound nucleotide but instead only locally affected its structure. However, this structural alteration of KRAS was sufficient to disable guanine nucleotide exchange factor–mediated nucleotide exchange and prevent KRAS from binding to RAF. Thus, RRSP is a bacterial effector that represents a previously unrecognized class of protease that disconnects Ras from its signaling network while inducing limited structural disturbance in its target.
- 1 April 2018
- Published by Elsevier in Developmental Cell
- Vol. 45 (1) , 83-100.e7
The HCMV Assembly Compartment Is a Dynamic Golgi-Derived MTOC that Controls Nuclear Rotation and Virus Spread
- 1 April 2018
- Published by Elsevier in Developmental Cell
- Vol. 45 (1) , 83-100.e7
The HCMV Assembly Compartment Is a Dynamic Golgi-Derived MTOC that Controls Nuclear Rotation and Virus Spread
- Open Access
- 1 July 2017
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 292 (30) , 12544-12559
Flexible-body motions of calmodulin and the farnesylated hypervariable region yield a high-affinity interaction enabling K-Ras4B membrane extraction
- 1 July 2017
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 292 (30) , 12544-12559
Open AccessFlexible-body motions of calmodulin and the farnesylated hypervariable region yield a high-affinity interaction enabling K-Ras4B membrane extraction
- 1 March 2017
- Published by Elsevier in Trends in Cancer
- Vol. 3 (3) , 214-224
Calmodulin and PI3K Signaling in KRAS Cancers
- 1 March 2017
- Published by Elsevier in Trends in Cancer
- Vol. 3 (3) , 214-224
Calmodulin and PI3K Signaling in KRAS Cancers
- 1 February 2016
- Published by Elsevier in Current Opinion in Structural Biology
- Vol. 36, 10-17
The disordered hypervariable region and the folded catalytic domain of oncogenic K-Ras4B partner in phospholipid binding
- 1 February 2016
- Published by Elsevier in Current Opinion in Structural Biology
- Vol. 36, 10-17
The disordered hypervariable region and the folded catalytic domain of oncogenic K-Ras4B partner in phospholipid binding